| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Claudiu T Supuran | Q28211545 |
| Jean-Yves Winum | Q28321861 | ||
| P2093 | author name string | Shoukat Dedhar | |
| Paul C. McDonald | |||
| P2860 | cites work | The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy | Q24801373 |
| Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX | Q27657692 | ||
| Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships | Q28115959 | ||
| Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours | Q28138058 | ||
| The catalytic properties of human carbonic anhydrase IX | Q28202087 | ||
| Expression of the transmembrane carbonic anhydrases, CA IX and CA XII, in the human male excurrent ducts | Q28203175 | ||
| Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer | Q28206439 | ||
| A novel quasi-viral agent, MaTu, is a two-component system | Q28209256 | ||
| Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase | Q28216714 | ||
| Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment | Q28247998 | ||
| Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer | Q28250852 | ||
| Carbonic anhydrases: novel therapeutic applications for inhibitors and activators | Q28263238 | ||
| Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity | Q28266273 | ||
| Expression of MaTu-MN protein in human tumor cultures and in clinical specimens | Q28268829 | ||
| Why do cancers have high aerobic glycolysis? | Q28290710 | ||
| Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts | Q28303168 | ||
| Hypoxia-inducible expression of tumor-associated carbonic anhydrases | Q28647603 | ||
| Targeting hypoxia in cancer therapy | Q29615491 | ||
| Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study | Q30433038 | ||
| Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis | Q48678753 | ||
| Gastric pit cell hyperplasia and glandular atrophy in carbonic anhydrase IX knockout mice: studies on two strains C57/BL6 and BALB/C. | Q50095649 | ||
| Brain phenotype of carbonic anhydrase IX-deficient mice. | Q51010100 | ||
| Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. | Q51864014 | ||
| HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. | Q51996253 | ||
| A microenvironmental model of carcinogenesis. | Q53326346 | ||
| Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. | Q53541890 | ||
| Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer. | Q53580661 | ||
| Carbonic anhydrase gene expression in CA II-deficient (Car2-/-) and CA IX-deficient (Car9-/-) mice. | Q54623823 | ||
| Expression of carbonic anhydrase IX in mouse tissues. | Q54700391 | ||
| Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma | Q57377955 | ||
| Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast cancer cell lines | Q58863231 | ||
| Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix | Q59139010 | ||
| Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney | Q68974069 | ||
| Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors | Q71542477 | ||
| Carbonic anhydrase inhibitors: aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors | Q73351038 | ||
| Carbonic anhydrase IX/G250/MN: a molecule too good to be true? | Q80654070 | ||
| Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer | Q81813519 | ||
| Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer | Q82276673 | ||
| Serum carbonic anhydrase IX during first-line therapy of ovarian cancer | Q82407168 | ||
| Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer | Q83434526 | ||
| Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients | Q84587308 | ||
| Intact intracellular tail is critical for proper functioning of the tumor-associated, hypoxia-regulated carbonic anhydrase IX. | Q39782884 | ||
| In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives | Q39823779 | ||
| The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths | Q39848831 | ||
| PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines | Q39864792 | ||
| Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. | Q39899643 | ||
| Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors | Q40133103 | ||
| Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia | Q40233525 | ||
| The role of carbonic anhydrase IX overexpression in kidney cancer | Q40347130 | ||
| Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. | Q40449476 | ||
| Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. | Q40489574 | ||
| Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion | Q40519856 | ||
| Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. | Q40687152 | ||
| Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation | Q42148565 | ||
| Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype | Q42508648 | ||
| Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. | Q42723906 | ||
| Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. | Q42747961 | ||
| 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range | Q42822569 | ||
| Coumarins incorporating hydroxy- and chloro-moieties selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II. | Q43004616 | ||
| The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors | Q43276919 | ||
| Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. | Q43829352 | ||
| Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model | Q43829857 | ||
| Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer | Q44342278 | ||
| Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody. | Q44398207 | ||
| Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging | Q44477869 | ||
| Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer | Q44620601 | ||
| Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with β-catenin | Q44624407 | ||
| Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re | Q44762750 | ||
| Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells | Q44793166 | ||
| Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. | Q45238896 | ||
| A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients | Q45250754 | ||
| Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker | Q46541391 | ||
| Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas | Q47343703 | ||
| Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. | Q47654612 | ||
| Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract | Q47717968 | ||
| Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma | Q47887068 | ||
| Expression of carbonic anhydrases IX and XII during mouse embryonic development | Q30816333 | ||
| Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology | Q33540178 | ||
| The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis | Q33557891 | ||
| Selection of Carbonic Anhydrase IX Inhibitors from One Million DNA-Encoded Compounds | Q33780700 | ||
| Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer | Q33790591 | ||
| Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX. | Q33818995 | ||
| High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer | Q33903731 | ||
| Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. | Q34093272 | ||
| A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma | Q34111751 | ||
| Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression | Q34192789 | ||
| Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. | Q34808815 | ||
| Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer | Q35608684 | ||
| Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. | Q35746400 | ||
| Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. | Q36610569 | ||
| DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. | Q36732878 | ||
| The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. | Q37081132 | ||
| Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. | Q37141969 | ||
| Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? | Q37161440 | ||
| Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours | Q37330712 | ||
| Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study | Q37350764 | ||
| Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target | Q37579348 | ||
| Generating specificity and diversity in the transcriptional response to hypoxia | Q37626406 | ||
| Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy | Q37723006 | ||
| Carbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007 - 2009. | Q37754473 | ||
| Carbonic Anhydrase IX as an Anticancer Therapy Target: Preclinical Evaluation of Internalizing Monoclonal Antibody Directed to Catalytic Domain | Q37785571 | ||
| pH control mechanisms of tumor survival and growth | Q37790658 | ||
| New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation | Q37796596 | ||
| Hypoxia and energetic tumour metabolism | Q37809288 | ||
| Interfering with pH regulation in tumours as a therapeutic strategy | Q37933052 | ||
| GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. | Q38602274 | ||
| Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. | Q39450874 | ||
| Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors | Q39488612 | ||
| Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. | Q39574525 | ||
| Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion | Q39583766 | ||
| Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells. | Q39697199 | ||
| P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antineoplastic | Q2853144 |
| medical oncology | Q6050805 | ||
| carbonic anhydrase | Q284089 | ||
| targeted therapy | Q492646 | ||
| neoplasm | Q1216998 | ||
| neoplasm antigens | Q76832457 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 84-97 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Recent developments in targeting carbonic anhydrase IX for cancer therapeutics | |
| P478 | volume | 3 |
| Q33860879 | 3'UTR polymorphisms of carbonic anhydrase IX determine the miR-34a targeting efficiency and prognosis of hepatocellular carcinoma |
| Q33884816 | 5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells |
| Q61455819 | A Flexible Synthesis of Ga-Labeled Carbonic Anhydrase IX (CAIX)-Targeted Molecules via CBT/1,2-Aminothiol Click Reaction |
| Q31140231 | A class of carbonic anhydrase I - selective activators. |
| Q27318442 | A membrane-type-1 matrix metalloproteinase (MT1-MMP)-discoidin domain receptor 1 axis regulates collagen-induced apoptosis in breast cancer cells |
| Q37211695 | A potential diagnostic marker for ovarian cancer: Involvement of the histone acetyltransferase, human males absent on the first |
| Q36148199 | A sucrose-binding site provides a lead towards an isoform-specific inhibitor of the cancer-associated enzyme carbonic anhydrase IX. |
| Q37559487 | Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma |
| Q37699173 | Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies. |
| Q47903791 | Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. |
| Q91914216 | Advances in Anti-Cancer Drug Development Targeting Carbonic Anhydrase IX and XII |
| Q38186073 | Agents described in the Molecular Imaging and Contrast Agent Database for imaging carbonic anhydrase IX expression |
| Q47096060 | An update on anticancer drug development and delivery targeting carbonic anhydrase IX. |
| Q38872439 | Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia |
| Q92859626 | Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice |
| Q38965239 | Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models |
| Q58539473 | Assessment of the antiproliferative and apoptotic roles of sulfonamide carbonic anhydrase IX inhibitors in HeLa cancer cell line |
| Q46852154 | Bicarbonate transport inhibitor SITS modulates pH homeostasis triggering apoptosis of Dalton's lymphoma: implication of novel molecular mechanisms |
| Q53072001 | Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers. |
| Q52715487 | Cancer Drug Development of Carbonic Anhydrase Inhibitors beyond the Active Site. |
| Q42087182 | Carbonic anhydrase 9 (CA9) and redox signaling in cancer-associated fibroblasts: therapeutic implications |
| Q56928085 | Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival |
| Q92158061 | Carbonic anhydrase II in complex with carboxylic acid-based inhibitors |
| Q91826315 | Carbonic anhydrase IX and acid transport in cancer |
| Q38154554 | Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases |
| Q57815591 | Carbonic anhydrase IX enhances tumor cell proliferation and tumor progression in osteosarcoma |
| Q38836322 | Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment |
| Q42935336 | Carborane-based carbonic anhydrase inhibitors: insight into CAII/CAIX specificity from a high-resolution crystal structure, modeling, and quantum chemical calculations. |
| Q43185297 | Carving out its niche: A role for carbonic anhydrase IX in pre-metastatic niche development. |
| Q40112666 | Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial |
| Q51112888 | Chemometric modeling of breast cancer associated carbonic anhydrase IX inhibitors belonging to the ureido-substituted benzene sulfonamide class. |
| Q36569050 | Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer |
| Q36640636 | Combination of lactate calcium salt with 5-indanesulfonamide and α-cyano-4-hydroxycinnamic acid to enhance the antitumor effect on HCT116 cells via intracellular acidification |
| Q52362933 | Coordinated Regulation of Metabolic Transporters and Migration/Invasion by Carbonic Anhydrase IX. |
| Q37735639 | Crucial role of carbonic anhydrase IX in tumorigenicity of xenotransplanted adult T-cell leukemia-derived cells |
| Q57300400 | Crystallography and Its Impact on Carbonic Anhydrase Research |
| Q34384442 | DNA hypomethylation-mediated overexpression of carbonic anhydrase 9 induces an aggressive phenotype in ovarian cancer cells |
| Q42511795 | Depletion of carbonic anhydrase IX abrogates hypoxia-induced overexpression of stanniocalcin-1 in triple negative breast cancer cells |
| Q38428521 | Designing carbonic anhydrase inhibitors for the treatment of breast cancer. |
| Q33746663 | Development and characterization of new monoclonal antibodies against human recombinant CA XII. |
| Q48060972 | Discovery of Strecker-type α-aminonitriles as a new class of human carbonic anhydrase inhibitors using differential scanning fluorimetry. |
| Q60921646 | Do CO2 and oxidative stress induce cancer?: a brief study about the evaluation of PON 1, CAT, CA and XO enzyme levels on head and neck cancer patients |
| Q39254783 | Down regulation of CAII is associated with tumor differentiation and poor prognosis in patients with pancreatic cancer |
| Q35564317 | Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation. |
| Q50044586 | Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide |
| Q47277628 | Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins |
| Q51825149 | Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. |
| Q38102745 | Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors |
| Q35148025 | Expression of hypoxic marker carbonic anhydrase IX predicts poor prognosis in resectable hepatocellular carcinoma |
| Q57809062 | Expression of renal cell markers and detection of 3p loss links endolymphatic sac tumor to renal cell carcinoma and warrants careful evaluation to avoid diagnostic pitfalls |
| Q45084779 | FGF2 as a potential prognostic biomarker for proneural glioma patients |
| Q51531366 | Fluorinated benzenesulfonamide anticancer inhibitors of carbonic anhydrase IX exhibit lower toxic effects on zebrafish embryonic development than ethoxzolamide. |
| Q91995012 | Harnessing Induced Essentiality: Targeting Carbonic Anhydrase IX and Angiogenesis Reduces Lung Metastasis of Triple Negative Breast Cancer Xenografts |
| Q38082457 | Head and neck cancer: from anatomy to biology |
| Q91990910 | Hepatocellular Carcinoma with Irregular Rim-Like Arterial Phase Hyperenhancement: More Aggressive Pathologic Features |
| Q35686653 | High expression of carbonic anhydrase IX is significantly associated with glandular lesions in gastroesophageal junction and with tumorigenesis markers BMI1, MCM4 and MCM7 |
| Q58741150 | Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma |
| Q38105251 | How far is the horizon? From current targets to future drugs in advanced renal cancer. |
| Q38653464 | How many carbonic anhydrase inhibition mechanisms exist? |
| Q38865279 | Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo |
| Q55251890 | Hypoxia-targeted gold nanorods for cancer photothermal therapy. |
| Q38395896 | Hypoxic tumor microenvironment in advanced retinoblastoma. |
| Q36502358 | Identification of metastasis-associated genes in colorectal cancer using metaDE and survival analysis |
| Q42790821 | Identifying the stromal cell type that contributes to tumor aggressiveness associated with carbonic anhydrase IX. |
| Q47227510 | Impact of tumoral carbonic anhydrase IX and Ki-67 expression on survival in oral squamous cell carcinoma patients |
| Q48044213 | In Silico Study, Synthesis, and Cytotoxic Activities of Porphyrin Derivatives |
| Q36480199 | In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors |
| Q58211544 | Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cellsin vitro |
| Q36673491 | Insights towards sulfonamide drug specificity in α-carbonic anhydrases |
| Q41844894 | Interaction of HIF-1α and Notch3 Is Required for the Expression of Carbonic Anhydrase 9 in Breast Carcinoma Cells |
| Q89519075 | Interrogating Bronchoalveolar Lavage Samples via Exclusion-Based Analyte Extraction |
| Q26849504 | Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia? |
| Q39782661 | Isoform-selective inhibitory profile of 2-imidazoline-substituted benzene sulfonamides against a panel of human carbonic anhydrases |
| Q37218017 | Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis |
| Q36729549 | Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma |
| Q90153550 | Microsecond Simulation of the Proteoglycan-like Region of Carbonic Anhydrase IX and Design of Chemical Inhibitors Targeting pH Homeostasis in Cancer Cells |
| Q39110234 | Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy |
| Q54297430 | Monoclonal antibodies raised against 167-180 aa sequence of human carbonic anhydrase XII inhibit its enzymatic activity. |
| Q92210340 | New Monoclonal Antibodies for a Selective Detection of Membrane-Associated and Soluble Forms of Carbonic Anhydrase IX in Human Cell Lines and Biological Samples |
| Q90117454 | New power of self-assembling carbonic anhydrase inhibitor: Short peptide-constructed nanofibers inspire hypoxic cancer therapy |
| Q26795678 | New ways to image and target tumour hypoxia and its molecular responses |
| Q38728290 | Newcastle disease virus degrades HIF-1α through proteasomal pathways independent of VHL and p53. |
| Q89128103 | Nitroimidazole-based inhibitors DTP338 and DTP348 are safe for zebrafish embryos and efficiently inhibit the activity of human CA IX in Xenopus oocytes |
| Q44420598 | Novel antibody to a carbonic anhydrase: patent evaluation of WO2011138279A1. |
| Q36238964 | Novel derivative of aminobenzenesulfonamide (3c) induces apoptosis in colorectal cancer cells through ROS generation and inhibits cell migration |
| Q30379739 | Novel multifunctional pH-sensitive nanoparticles loaded into microbubbles as drug delivery vehicles for enhanced tumor targeting |
| Q45326891 | Novel sulfonamide compounds for inhibition of metastatic tumor growth (WO2012021963). |
| Q38521920 | Nuclear imaging of renal tumours: a step towards improved risk stratification |
| Q38974704 | Oncogenic roles of carbonic anhydrase IX in human nasopharyngeal carcinoma |
| Q26749333 | Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction |
| Q48212596 | Overcoming the Limits of Hypoxia in Photodynamic Therapy: A Carbonic Anhydrase IX-Targeted Approach. |
| Q47786737 | Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma |
| Q42177054 | PML promotes metastasis of triple-negative breast cancer through transcriptional regulation of HIF1A target genes. |
| Q47097799 | Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX. |
| Q36392145 | Phospho-ΔNp63α/SREBF1 protein interactions: bridging cell metabolism and cisplatin chemoresistance |
| Q45908190 | Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases. |
| Q48196778 | Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization. |
| Q112614605 | Prediction of activity and selectivity profiles of human Carbonic Anhydrase inhibitors using machine learning classification models |
| Q48110370 | Primary mono- and bis-sulfonamides obtained via regiospecific sulfochlorination of N-arylpyrazoles: inhibition profile against a panel of human carbonic anhydrases. |
| Q38937979 | Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells. |
| Q42269128 | Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy |
| Q47809412 | Quantitative assessment of specific carbonic anhydrase inhibitors effect on hypoxic cells using electrical impedance assays |
| Q91704707 | ROC-1, P21 and CAIX as markers of tumor aggressiveness in bladder carcinoma in Egyptian patients |
| Q38734017 | Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models |
| Q38957845 | Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance |
| Q48552373 | Rethinking the Combination of Proton Exchanger Inhibitors in Cancer Therapy |
| Q38184984 | Role of pHi, and proton transporters in oncogene-driven neoplastic transformation |
| Q35157417 | Saccharin: a lead compound for structure-based drug design of carbonic anhydrase IX inhibitors. |
| Q28077999 | Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins |
| Q64969038 | Selective inhibition of carbonic anhydrase-IX by sulphonamide derivatives induces pH and reactive oxygen species-mediated apoptosis in cervical cancer HeLa cells. |
| Q38750372 | Selective inhibition of human carbonic anhydrase IX in Xenopus oocytes and MDA-MB-231 breast cancer cells |
| Q34394097 | Structural insights into carbonic anhydrase IX isoform specificity of carbohydrate-based sulfamates |
| Q51079634 | Structure activity study of carbonic anhydrase IX: Selective inhibition with ureido-substituted benzenesulfonamides. |
| Q37999063 | Structure-based drug discovery of carbonic anhydrase inhibitors |
| Q47756079 | Sulfocoumarin-, Coumarin-, 4-Sulfamoylphenyl-Bearing Indazole-3-carboxamide Hybrids: Synthesis and Selective Inhibition of Tumor-Associated Carbonic Anhydrase Isozymes IX and XII. |
| Q36546587 | Sulfonamide derivative targeting carbonic anhydrase IX as a nuclear imaging probe for colorectal cancer detection in vivo |
| Q38018632 | Sulfonamides: a patent review (2008 - 2012). |
| Q90402926 | Sweet Binders: Carbonic Anhydrase IX in Complex with Sucralose |
| Q29248727 | Switching off malignant mesothelioma: exploiting the hypoxic microenvironment |
| Q51089283 | Synthesis of an acridine orange sulfonamide derivative with potent carbonic anhydrase IX inhibitory action. |
| Q92678251 | Synthesis of saccharin-glycoconjugates targeting carbonic anhydrase using a one-pot cyclization/deprotection strategy |
| Q43125262 | TRPM5 mediates acidic extracellular pH signaling and TRPM5 inhibition reduces spontaneous metastasis in mouse B16-BL6 melanoma cells |
| Q37030920 | Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma |
| Q38342634 | Targeting carbonic anhydrase IX activity and expression. |
| Q28822228 | Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors |
| Q34401785 | Targeting hypoxia in the leukemia microenvironment |
| Q38263008 | Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium |
| Q92258464 | The Role of Sodium Hydrogen Exchanger 1 in Dysregulation of Proton Dynamics and Reprogramming of Cancer Metabolism as a Sequela |
| Q52665387 | The cytotoxic, apoptotic and oxidative effects of carbonic anhydrase IX inhibitor on colorectal cancer cells. |
| Q43511621 | The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion. |
| Q26827175 | The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo |
| Q37214341 | The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma |
| Q64956341 | Topiramate exhibits anti-tumorigenic and metastatic effects in ovarian cancer cells. |
| Q34513382 | Tumor metabolism, cancer cell transporters, and microenvironmental resistance |
| Q34205104 | Tumor microenvironmental changes induced by the sulfamate carbonic anhydrase IX inhibitor S4 in a laryngeal tumor model |
| Q92508836 | Type 1 Sodium Calcium Exchanger Forms a Complex with Carbonic Anhydrase IX and Via Reverse Mode Activity Contributes to pH Control in Hypoxic Tumors |
| Q27698086 | X-ray crystallographic and kinetic investigations of 6-sulfamoyl-saccharin as a carbonic anhydrase inhibitor |
| Q35497226 | ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH. |
| Q36621603 | [(18)F]VM4-037 MicroPET Imaging and Biodistribution of Two In Vivo CAIX-Expressing Tumor Models. |
Search more.